Bifidobacterium adolescentis AGE17 for promoting muscle and bone growth and development and application thereof

Abstract

The application relates to the field of microbial technology, and particularly discloses a Bifidobacterium adolescentis AGE17 for promoting muscle and bone growth and development and an application thereof. Bifidobacterium adolescentis The Bifidobacterium adolescentis AGE17 is isolated from the feces of healthy children, is preserved in the China General Microbiological Culture Collection Center, and has a preservation number of CGMCC No. 33452 and a preservation date of January 17, 2025. Animal experiments prove that the Bifidobacterium adolescentis strain AGE17 provided by the application has the function of promoting muscle and bone development, has more obvious and prominent effects compared with a model strain Bifidobacterium adolescentis ATCC15703, and has important application values in increasing the muscle strength and height of children and teenagers.

Description

Technical Field

[0001] This invention relates to the field of microbial technology, and in particular to a Bifidobacterium adolescentis strain AGE17 that promotes muscle and bone growth and development and its applications. Background Technology

[0002] Current interventions for child / adolescent development mainly rely on hormones or nutritional supplements (such as calcium and protein), which carry risks of side effects (such as precocious puberty) or low absorption efficiency.

[0003] Compared to existing nutritional supplements, probiotics offer numerous advantages in promoting physical development. During childhood and adolescence, scientifically supplementing with probiotics can better help establish a healthy gut microbiota barrier, strengthen the immune system, improve nutrient absorption, and ensure healthy growth.

[0004] Existing functional studies on Bifidobacterium adolescentis mainly focus on its role in improving physical aging. For example, Bifidobacterium adolescentis ATCC15703 can extend lifespan and alleviate age-related sarcopenia (Zeng Zhang, 2025). The soluble polysaccharide components of Bifidobacterium adolescentis ATCC15703 can combat intestinal aging (CN116870037B). Bifidobacterium adolescentis also has a beneficial effect on osteoporosis associated with aging (CN119955658A). However, whether Bifidobacterium adolescentis can promote development in children and adolescents remains unclear. Summary of the Invention

[0005] In order to address the problems existing in the prior art, the purpose of this invention is to provide a strain of Bifidobacterium adolescentis that can promote muscle and bone development in children and adolescents, thus providing a new nutritional solution for the growth and development of children and adolescents.

[0006] To achieve the objectives of this invention, the technical solution is as follows:

[0007] In a first aspect, the present invention provides a strain of Bifidobacterium adolescentis (Bifidobacterium adolescentis) Bifidobacterium adolescentis AGE17, the Bifidobacterium adolescentis ( Bifidobacterium adolescentis AGE17 is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 33452 and deposit date of January 17, 2025.

[0008] The Bifidobacterium adolescentis AGE17 is tolerant to gastric and intestinal juices in the digestive tract and has the potential to be developed into an edible probiotic.

[0009] In a second aspect, the present invention provides a composition containing the aforementioned Bifidobacterium adolescentis AGE17.

[0010] Furthermore, the composition is a microbial preparation, and the viable count of the Bifidobacterium adolescentis AGE17 in the microbial preparation is not less than 1 × 10⁻⁶. 9 CFU / mL or 1×10 9 CFU / g, or cell count not less than 1×10⁻⁶ 9 The composition may contain live and / or inactivated Bifidobacterium adolescentis AGE17 bacteria. When live bacteria are present, the live count is not less than 1 × 10⁻⁶. 9 CFU / mL or 1×10 9 CFU / g; when containing inactivated bacteria, the cell count should not be less than 1×10⁻⁶. 9 per g.

[0011] Thirdly, the present invention provides a product containing the aforementioned Bifidobacterium adolescentis AGE17.

[0012] Furthermore, the product is a pharmaceutical, food, or health supplement. The product form includes, but is not limited to, tablets, powders, and liquid formulations.

[0013] The product may also contain live and / or inactivated Bifidobacterium adolescentis AGE17.

[0014] Fourthly, the present invention provides the application of the aforementioned Bifidobacterium adolescentis AGE17 in promoting muscle growth and development.

[0015] Fifthly, the present invention provides the application of the aforementioned Bifidobacterium adolescentis AGE17 in promoting bone growth and development.

[0016] Sixthly, the present invention provides the application of the aforementioned Bifidobacterium adolescentis AGE17 in the preparation of pharmaceuticals, foods or health products for promoting muscle growth and development.

[0017] In a seventh aspect, the present invention provides the application of the aforementioned Bifidobacterium adolescentis AGE17 in the preparation of pharmaceuticals, foods or health products for promoting bone growth and development.

[0018] Furthermore, the aforementioned promotion of muscle growth and development specifically manifests as an increase in muscle layer thickness and muscle weight, while also not excluding positive effects such as thickening of muscle fibers.

[0019] Furthermore, animal experiments using model organisms and mice have demonstrated that the Bifidobacterium adolescentis AGE17 provided by this invention has a significant effect on promoting muscle and bone growth and development in organisms in the growth stage. Therefore, the above applications are preferably targeted at children or adolescents in the growth stage.

[0020] The beneficial effects of this invention are as follows:

[0021] This invention isolates and provides a Bifidobacterium adolescentis strain AGE17, which, through animal experiments, has been shown to promote muscle and bone development, exhibiting a more significant and pronounced effect compared to the model strain ATCC15703. Therefore, Bifidobacterium adolescentis strain AGE17 has significant application value in increasing muscle strength and height in children and adolescents, specifically in the preparation of medicines, foods, and health products that promote muscle and bone development in children and adolescents. Attached Figure Description

[0022] The accompanying drawings, which are incorporated in and form part of this specification, illustrate embodiments consistent with the invention and, together with the description, serve to explain the principles of the invention.

[0023] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, for those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0024] Figure 1 This is a single colony morphology diagram of Bifidobacterium adolescentis AGE17.

[0025] Figure 2 Gram staining micrograph of Bifidobacterium adolescentis AGE17.

[0026] Figure 3 The image shows fluorescent staining of the body wall muscle of *C. elegans* at different time points in Example 3. Detailed Implementation

[0027] To better understand the above-mentioned objectives, features, and advantages of the present invention, the present invention will be further described below.

[0028] Many specific details are set forth in the following description in order to provide a full understanding of the invention, but the invention may also be practiced in other ways different from those described herein; obviously, the embodiments in the specification are only some embodiments of the invention, and not all embodiments.

[0029] The preferred embodiments of the present invention will now be described in detail with reference to specific examples. It should be understood that the following examples are given for illustrative purposes only and are not intended to limit the scope of the invention. Those skilled in the art can make various modifications and substitutions to the present invention without departing from its spirit and essence.

[0030] The Bifidobacterium culture medium used in the following examples was purchased commercially from Qingdao Haibo Biotechnology Co., Ltd., and its components (g / L) were: tryptone 5.0; soybean peptone 5.0; yeast extract 10.0; glucose 10.0; L-cysteine ​​0.5; resazurite 0.001; potassium dihydrogen phosphate 0.04; dipotassium hydrogen phosphate 0.04; sodium bicarbonate 0.4; sodium chloride 0.08; calcium chloride 0.008; magnesium sulfate 0.0192; agar 15.0; pH 7.0.

[0031] Unless otherwise specified, the experimental methods used in the following examples are conventional methods.

[0032] Unless otherwise specified, all materials and reagents used in the following examples are commercially available.

[0033] Example 1: Origin, isolation, and identification of Bifidobacterium adolescentis AGE17

[0034] The Bifidobacterium adolescentis AGE17 of this invention was isolated from the feces of healthy children and was deposited on January 17, 2025 at the China General Microbiological Culture Collection Center (address: No. 3, No. 1 Beichen West Road, Chaoyang District, Beijing), with accession number CGMCC No. 33452.

[0035] The specific isolation steps are as follows: Take 1g of healthy child's fecal sample and add 5mL of Bifidobacterium medium, then anaerobically enrich at 37℃ for 24 hours. Take the enriched culture and serially dilute it with sterile 1*PBS solution. Spread 100μL of the diluted solution onto Bifidobacterium agar plates. Place the plates in an anaerobic chamber, seal tightly, and incubate at 37℃ for 72 hours. Pick the round, convex white colonies that have grown on the plates and inoculate them into Bifidobacterium medium, then anaerobically incubate at 37℃ for 48 hours. Add an equal volume of 50% glycerol to the culture medium for preservation.

[0036] Take the remaining bacterial culture medium from the preservation step, use the culture medium as a template, and perform PCR amplification using the 16S universal primers 27F / 1492R. Send the amplification product to a sequencing company for sequencing. The sequencing sequence is shown in SEQ ID No. 1.

[0037] The sequencing results were submitted to the NCBI database for online comparison, and the comparison result was Bifidobacterium adolescentis (…). Bifidobacterium adolescentis The strain was named Bifidobacterium adolescentis AGE17. Bifidobacterium of a young man AGE17).

[0038] Dilute and plate the culture medium of Bifidobacterium adolescentis AGE17 onto agar plates, and incubate anaerobically for 48 hours. The colony morphology of Bifidobacterium adolescentis AGE17 on Bifidobacterium agar plates is: white, smooth, convex in the middle, with intact edges, and shiny, round colonies. Figure 1 ).

[0039] A thin, even spread of Bifidobacterium adolescentis AGE17 bacterial suspension was taken and Gram-stained, then observed under an oil immersion microscope. The microscopic photograph is shown below. Figure 2 As shown: Bifidobacterium adolescentis is Gram-positive for AGE17 staining. The bacteria are short rods, arranged singly or in pairs, without spores or flagella.

[0040] Example 2: Assessment of the gastrointestinal viability of Bifidobacterium adolescentis AGE17

[0041] To compare and evaluate the survival ability of Bifidobacterium adolescentis AGE17 in the gastrointestinal tract, the model strain Bifidobacterium adolescentis ATCC15703 was selected as the control strain for culture tests in simulated gastric and intestinal fluids.

[0042] Bifidobacterium adolescentis AGE17 and ATCC15703 were inoculated into Bifidobacterium culture medium and cultured for 24 hours. After centrifugation, the cultured cells were collected, washed with sterile PBS, and resuspended in artificial gastric and intestinal fluids, respectively. The cells were then diluted and plated to determine the viability count at 0 hours.

[0043] After anaerobic incubation at 37°C for 2 hours, the bacterial count was determined by dilution and plate testing (see Table 1). After 2 hours of incubation in simulated gastric fluid, the survival rate of *Bifidobacterium adolescentis* ATCC15703 was 34.8%, and the survival rate of *Bifidobacterium adolescentis* AGE17 was 74.8%. After 2 hours of incubation in simulated intestinal fluid, the survival rate of *Bifidobacterium adolescentis* ATCC15703 was 26.2%, and the survival rate of *Bifidobacterium adolescentis* AGE17 was 63.4%.

[0044] The above results indicate that compared to Bifidobacterium adolescentis ATCC15703, Bifidobacterium adolescentis AGE17 has a stronger ability to tolerate gastric and intestinal fluids and can exhibit a higher survival rate in the gastrointestinal tract.

[0045] Table 1. Results of comparative test on gastrointestinal viability

[0046]

[0047] Example 3: Bifidobacterium adolescentis AGE17 promotes the growth and development of Caenorhabditis elegans.

[0048] Caenorhabditis elegans is widely used as a biological model for studying growth and development, as its body wall muscles are similar in function and structure to those of vertebrate skeletal muscles.

[0049] This invention uses the N2 strain of *C. elegans* as the research object to test the effect of *Bifidobacterium adolescentis* AGE17 on the growth and development of nematodes. The control strain is the model strain *Bifidobacterium adolescentis* ATCC15703.

[0050] 1. Escherichia coli OP50 cultured in LB medium until OD600 reached 1.0, then added to prepared NGM solid plates and incubated overnight at 37°C. The NGM solid plates were then collected for the culture of Caenorhabditis elegans.

[0051] The culture medium for Caenorhabditis elegans was NGM solid medium, and the culture temperature was 20℃.

[0052] The preparation method of the NGM solid culture medium is as follows: Weigh 2.5g of peptone, 3g of sodium chloride, 17g of agar, and 950g of deionized water. Autoclave at 121℃ for 20 minutes. After cooling to 55℃, add 1mL of 1mol / L calcium chloride, 1mL of 1mol / L magnesium sulfate, 1mL of 5mg / mL calcium chloride, and 25mL of 1mol / L phosphate buffer. Mix well and pour into a sterile 60mm plastic petri dish to solidify.

[0053] 2. Nematode synchronization using the lysis method: Collect nematodes and add 500 μL of lysis buffer for 4 minutes. Immediately add 500 μL of M9 buffer, centrifuge at 500g for 1 minute, discard the supernatant, and wash the precipitate three times with 1 mL of M9 buffer. After washing, resuspend the Caenorhabditis elegans eggs in an appropriate amount of M9 buffer. Add the eggs to NGM solid plates without E. coli OP50 and incubate at 20°C for 16 hours to obtain synchronized L1 nematodes.

[0054] The formulation of the nematode lysis buffer is as follows: 2 mL of 4% sodium hypochlorite solution; 2 mL of 2.5 mol / L sodium hydroxide solution; 6 mL of sterile water.

[0055] The formulation of the M9 buffer solution is as follows (g / L): potassium dihydrogen phosphate 3; disodium hydrogen phosphate 6; sodium chloride 5; magnesium sulfate 0.12.

[0056] 3. Preparation of NGM plates with different strains:

[0057] (1) Blank group: Add 100 μL of Escherichia coli OP50 bacterial solution to NGM solid plate and incubate overnight at 37°C.

[0058] (2) Control group: Take 1 mL of bacteria with a concentration of 5×10 8 The CFU / mL Bifidobacterium adolescentis ATCC15703 bacterial suspension was heat-inactivated at 100℃ for 30 minutes, centrifuged at 12000g for 1 minute to remove the supernatant, resuspended in 1 mL of Escherichia coli OP50 bacterial suspension, and then 100 μL was added to NGM solid plates and incubated overnight at 37℃.

[0059] (3) AGE17 group: Take 1 mL of a concentration of 5×10 8 CFU / mL Bifidobacterium adolescentis AGE17 bacterial suspension was heat-inactivated at 100℃ for 30 minutes, centrifuged at 12000g for 1 minute to remove the supernatant, resuspended in 1 mL of Escherichia coli OP50 bacterial suspension, and then 100 μL was added to NGM solid plates and incubated overnight at 37℃.

[0060] 4. Synchronized L1 nematodes were inoculated onto NGM solid plates of the blank group, control group, and AGE17 group, respectively. Each plate was inoculated with 150 nematodes and placed in an incubator at 20°C. Nematodes were collected from each group's plates at 24, 48, and 72 hours, and stained with rhodamine-phalloidin.

[0061] The staining procedure was as follows: 100 μL of acetone was added to the EP tube containing the collected nematodes, and the tube was allowed to stand at room temperature for 5 minutes. After centrifugation at 500g for 30 seconds, the acetone was removed as much as possible. After the remaining acetone evaporated, 100 μL of a 1:200 diluted rhodamine-phalloidin staining solution was added, and the tube was stained in the dark for 30 minutes. After centrifugation to remove the staining solution, the tube was washed three times with M9 buffer. The nematodes were then transferred to a glass slide, the solution on the slide was removed, and 20 μL of anti-fluorescence quenching mounting solution containing DAPI was added. The slide was gently covered with a coverslip, and the tube was allowed to stand in the dark until the mounting solution solidified. The fluorescently labeled nematode body wall muscle was then observed using a fluorescence microscope.

[0062] from Figure 3 It can be seen that after 24 hours of culture, the three groups of nematodes showed red fluorescence only on the surface of their bodies, with no fluorescence signal on the inner side of their body walls. After 48 hours of culture, the muscle layer on the inner side of the body wall of the nematodes in the blank group and the control group was very thin, while the muscle layer in the AGE17 group was thicker, with the muscles forming bundles and the linear muscle fibers clearly visible. After 72 hours of culture, all three groups of nematodes had developed into adults, and bundles of muscle had formed on the inner side of their body walls, but the muscle layer thickness of the AGE17 group was still greater than that of the other two groups. This indicates that heat-inactivated Bifidobacterium adolescentis AGE17 can promote muscle growth in *C. elegans*.

[0063] After fluorescence observation, the slide was placed under a regular optical microscope for observation. After photographing, the length of the nematodes was measured using ImageJ software, and the statistical results are shown in Table 2. At 48 hours, the nematode length in the AGE17 group was 4.03% and 9.12% longer than the blank group and the control group, respectively; at 72 hours, the nematode length in the AGE17 group was 11.96% and 14.50% longer than the blank group and the control group, respectively, indicating that heat-inactivated Bifidobacterium adolescentis AGE17 promoted nematode growth.

[0064] Table 2. Statistical analysis of Caenorhabditis elegans worm length at different time points

[0065]

[0066] The data in the table represent the mean ± standard deviation. a indicates a significant difference from the blank group; b indicates a significant difference from the control group (P value < 0.05).

[0067] Example 4: Bifidobacterium adolescentis AGE17 improves muscle strength in mice

[0068] Twenty-four male C57 mice were randomly divided into three groups: a control group, a control bacterial group, and an AGE17 group. Mice in all three groups underwent gavage intervention starting at 15 days of age, with an intervention period of 4 weeks (equivalent to childhood to mid-adolescence in humans). The AGE17 group and the control bacterial group received 1×10⁻⁶ mg / L gavage daily. 9 CFU of Bifidobacterium adolescentis AGE17 and control strain ATCC15703 were administered to mice via gavage, while the blank control group received an equal volume of physiological saline. Muscle strength was tested in mice 16 hours after the last gavage.

[0069] Grip strength test: Place the mouse on the gripping board, which is connected to the testing device. Once the mouse is firmly planted on the gripping board and stationary, gently grasp the base of the mouse's tail and pull horizontally and at a constant speed until the mouse releases its grip and detaches from the gripping board. Record the maximum pulling force value of the testing device.

[0070] 2. Rotary Bar Duration Test: Half an hour after the grip strength test, a balance rotary bar test was conducted. The mouse was placed on the rotary bar with its orientation opposite to the direction of rotation. The initial rotation speed of the rotary bar was 4 rpm. After the mouse stabilized, the rotary bar was accelerated uniformly to 40 rpm within 300 seconds, and the time it took for the mouse to fall off the rotary bar was recorded.

[0071] As shown in Table 3, the grip strength of mice in the AGE17 group was 17.51% and 9.93% higher than that in the blank group and the control group, respectively, and the rotarod dwell time was 20.33% and 17.41% higher than that in the blank group and the control group, respectively. This indicates that oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice increased the muscle strength of the mice.

[0072] Table 3 Mouse Muscle Strength Test Table

[0073]

[0074] The data in the table represent the mean ± standard deviation. a indicates a significant difference from the blank group; b indicates a significant difference from the control group (P value < 0.05).

[0075] Example 5: Bifidobacterium adolescentis AGE17 promotes muscle and bone development in mice.

[0076] This embodiment aims to detect muscle and bone development-related indicators in mice after completing the tests in Example 4.

[0077] The mice were placed on a bone density testing bed and analyzed by X-ray scanning. The whole-body scanning mode was used to record the bone density of each group of mice.

[0078] After recording the mouse weight, blood was collected from the eyeballs and an autopsy was performed. The mice were dissected, and the quadriceps femoris, tibialis anterior, and gastrocnemius muscles were separated and weighed. The muscle percentage was calculated as: muscle percentage = muscle weight ÷ body weight. The femur and tibia were taken and their lengths measured using calipers. The femur and tibia, after muscle removal, were soaked in anhydrous ether for 12 hours to defatt them, placed in a 105°C drying oven for 72 hours, and allowed to equilibrate at room temperature for 24 hours before weighing the bone. The bone index was calculated as: bone index = defatted bone weight ÷ bone length. Serum was separated, and the mouse serum calcium content, insulin-like growth factor 1 (IGF-1) level, and osteocalcin (OCN) level were measured according to the kit instructions.

[0079] As shown in Table 4, oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice increased the weight of the quadriceps femoris, tibialis anterior, and gastrocnemius muscles. The muscle proportions of the three muscles in the AGE17 group were higher than those in the blank group and the control group, indicating that Bifidobacterium adolescentis AGE17 promoted muscle growth in mice.

[0080] Table 4 Results of Mouse Muscle Measurement

[0081]

[0082] The data in the table represent the mean ± standard deviation. a indicates a significant difference from the blank group; b indicates a significant difference from the control group (P value < 0.05).

[0083] As shown in Table 5, AGE17 intervention significantly increased the length and weight of the femur and tibia, and the bone density was 12.4% higher than that of the blank group and 10.49% higher than that of the control group. This indicates that AGE17 intervention promoted bone growth in mice during their growth period and made their bones more compact.

[0084] Sufficient calcium and phosphorus in serum are beneficial for bone mineralization. Table 5 shows that serum calcium levels in the AGE17 group were 67.20% higher than in the control group. IGF-1 is the main hormone regulating linear bone growth; AGE17 intervention induced IGF-1 secretion, which was 21.64% higher than in the control group. Serum osteocalcin (OCN) is a product secreted and released into the bloodstream by osteoblasts during bone formation. Increased OCN levels indicate more vigorous bone formation in mice during their growth period; serum OCN levels after AGE17 intervention were 16.15% higher than in the control group.

[0085] These results indicate that oral administration of Bifidobacterium adolescentis AGE17 during the growth period of mice promotes bone growth by enhancing calcium metabolism, growth hormone secretion, and osteoblast differentiation.

[0086] Table 5. Results of analysis of mouse skeletal development related indicators

[0087]

[0088] The data in the table represent the mean ± standard deviation. a indicates a significant difference from the blank group; b indicates a significant difference from the control group (P value < 0.05).

[0089] Example 6: Inactivated Bifidobacterium adolescentis AGE17 probiotic product

[0090] Centrifuge the *Bifidobacterium adolescentis* AGE17 fermentation broth and collect the bacterial cells. Add 1-3 times the weight of the bacterial cells with a freeze-drying protectant (freeze-drying protectant w / w: 5-20% maltodextrin, 5-20% sucrose), mix well, heat-inactivate at 100℃ for 10-30 minutes, cool, and then transfer to a vacuum freeze dryer for freeze-drying. Collect the freeze-dried bacterial powder, grind it, and sieve it through a 30-mesh sieve. After sieving, use quantitative real-time PCR to calculate the number of inactivated *Bifidobacterium adolescentis* AGE17 cells in the sample. Add the bacterial powder to the final probiotic product; the amount of inactivated *Bifidobacterium adolescentis* AGE17 added to the final product is 1×10⁻⁶. 9 Up to 1×10 10 per g.

[0091] Example 7: Live Bifidobacterium adolescentis AGE17 probiotic product

[0092] Prepared using conventional methods according to different dosage forms, the product contains no less than 1×10⁻⁶ viable bacteria. 9 CFU / mL or 1×10 9 CFU / g.

[0093] The above description is merely a specific embodiment of the present invention, enabling those skilled in the art to understand or implement the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the present invention is not to be limited to the embodiments described herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A strain of Bifidobacterium adolescentis (B. adolescentis) AGE17, characterized in that, Bifidobacterium adolescentis )AGE17, characterized in that, Bifidobacterium adolescentis (ATCC 15703) Bifidobacterium adolescentis AGE17 was deposited with China General Microbiological Culture Collection Center on January 17, 2025, and was assigned accession number CGMCC No. 33452.

2. A composition comprising the Bifidobacterium adolescentis AGE 17 of claim 1.

3. The composition of claim 2, wherein, The composition is a microbial preparation, and the viable cell number of the Bifidobacterium adolescentis AGE17 in the microbial preparation is not less than 1 x 10 9 CFU / mL or 1 x 10 9 CFU / g, or the cell number is not less than 1 x 10 9 CFU / g.

4. A product characterized by, The product comprises the Bifidobacterium adolescentis AGE 17 of claim 1.

5. The product of claim 4, wherein, The product is a pharmaceutical product or a food product.

6. Use of the Bifidobacterium adolescentis AGE 17 of claim 1 for promoting muscle growth and development.

7. Use of the Bifidobacterium adolescentis AGE 17 of claim 1 for promoting bone growth and development.

8. Use of the Bifidobacterium adolescentis AGE 17 of claim 1 for the preparation of a pharmaceutical product or a food product for promoting muscle growth and development.

9. Use of the Bifidobacterium adolescentis AGE 17 of claim 1 for the preparation of a pharmaceutical product or a food product for promoting bone growth and development.

10. The use according to any one of claims 6 to 9, characterized in that, Promoting muscle or bone growth and development in a child or an adolescent in a growth phase.

Images